You just read:

Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors

News provided by

Blueprint Medicines

Apr 15, 2018, 09:30 ET